Last reviewed · How we verify
Artrodar
Artrodar is a Small molecule drug developed by TRB Chemedica. It is currently in Phase 3 development.
Artrodar is a small molecule with an unknown mechanism of action. It has been studied as a treatment for knee osteoarthritis, COVID-19, osteoarthritis, and conditions related to glucosamine, and has been compared to diacerein and placebos in clinical trials.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Artrodar |
|---|---|
| Sponsor | TRB Chemedica |
| Target | Caspase-3, Caspase-7, N-acylethanolamine-hydrolyzing acid amidase |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Structural Modification Effect of Diacerein (Artrodar®) in Knee Osteoarthritic Patients (PHASE3)
- Bioequivalence Study of Diacerein 50 mg Capsule in Healthy Thai Volunteers (PHASE1)
- Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis (PHASE3)
- Study Design of the Diacerein in Patients With Covid-19 (PHASE2)
- Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects (PHASE3)
- Effect of Interventions on the Progression of Knee Osteoarthritis (PHASE4)
- Clinical Efficacy of Glucosamine Plus Diacerein Versus Mono-therapy of Glucosamine (PHASE4)
- Effect of Diacerein in the Metabolic Control of Patients With DM Type 2 and Secondary Failure to Metformin (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Artrodar CI brief — competitive landscape report
- Artrodar updates RSS · CI watch RSS
- TRB Chemedica portfolio CI
Frequently asked questions about Artrodar
What is Artrodar?
Who makes Artrodar?
What development phase is Artrodar in?
What does Artrodar target?
Related
- Target: All drugs targeting Caspase-3, Caspase-7, N-acylethanolamine-hydrolyzing acid amidase
- Manufacturer: TRB Chemedica — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing